Share ownership Cybin Inc.

CYBN

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-12-12 pm EST			5-day change	1st Jan Change
6.680 ^USD	+6.03%		+11.52%	-24.26%

Nov. 18	Cybin Inc., Q2 2026 Earnings Call, Nov 13, 2025
Nov. 13	Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI

Share class: Cybin Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	20,001,406	18,722,152 ( 93.6 %)	0	93.6 %

Major shareholders: Cybin Inc.

Name	Equities	%	Valuation
Point72 Asset Management LP 8.621 %	4,301,440	8.621 %	27 M $
Venrock Associates 7.697 %	3,840,250	7.697 %	24 M $
Deep Track Capital LP 6.158 %	3,072,250	6.158 %	19 M $
Tang Capital Management LLC 3.668 %	1,830,097	3.668 %	11 M $
Tang Capital Management LLC 3.668 %	1,830,097	3.668 %	11 M $
Rosalind Advisors, Inc. 3.006 %	1,500,000	3.006 %	9 M $
Point72 Asset Management LP 2.485 %	1,239,629	2.485 %	8 M $
Deep Track Capital LP 2.004 %	1,000,000	2.004 %	6 M $
Acorn Capital Advisors LLC 1.472 %	734,394	1.472 %	5 M $
Sphera Funds Management Ltd. 0.7423 %	370,376	0.7423 %	2 M $
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	42.76%
Other	2.31%
Individuals	1.99%
Unknown	52.94%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	40.52%
Canada	3.12%
Individuals	1.99%
Israel	0.74%
Czech Republic	0.31%
United Kingdom	0.28%
Germany	0.07%
Luxembourg	0.03%

Based on 1000 largest holdings

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Employees

Sector

Biotechnology & Medical Research

Calendar

Feb. 16 - Q3 2026 Earnings Release (Projected)

More about the company